Hematologist
CION Cancer Clinics
High-risk cytogenetics in myeloma, explained | CION Cancer Clinics
High-risk cytogenetics means a chromosome test on your myeloma cells found a change linked with disease that may grow faster or return sooner. The main ones are del(17p), t(4;14), t(14;16), t(14;20) and extra copies of 1q. These changes are in the cancer cells only and are not inherited. A high-risk result shapes a stronger, closer-watched plan. It does not mean treatment will not help. At CION Cancer Clinics, our haematology team plans myeloma and lymphoma care with you, discussed at a tumour board and explained in plain words.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does "high-risk cytogenetics" mean in myeloma?
- Which chromosome changes count as high risk?
- How is the chromosome test done?
- If the result is high risk, what changes?
- What do families often fear wrongly about a high-risk result?
- How do you read the shorthand on a FISH report?
- Common questions about high-risk myeloma
The short answer
What does "high-risk cytogenetics" mean in myeloma?
It means a chromosome test on your myeloma cells found a change linked with disease that tends to grow faster or return sooner after treatment. The main ones are del(17p), t(4;14), t(14;16), t(14;20) and extra copies of chromosome 1q. It changes how the plan is built, not whether treatment is worth having.
What cytogenetics are
Cytogenetics is the study of chromosomes, the packages of genetic material inside each cell. Myeloma cells pick up changes in their chromosomes as they grow. These changes are in the cancer cells only. They are not something you were born with, and they are not passed on to your children.
Why the test matters
Two people can have the same stage and the same M-protein level but very different disease. The chromosome pattern is one of the strongest clues about how the myeloma will behave. It feeds into the R-ISS stage and helps your team decide how strong and how long treatment should be.
Standard risk is the most common result
Most people do not have a high-risk change. Their result is called standard risk. That is good news, but it still needs full treatment when the myeloma is active.
On the FISH report
Which chromosome changes count as high risk?
The lists used by expert groups have changed over the years and differ slightly. Your haematologist will tell you which ones apply to your report.
del(17p)
Part of the short arm of chromosome 17 is missing. That piece holds TP53, a gene that normally stops damaged cells from growing. It is one of the most important high-risk findings.
The share of cells carrying it matters, so ask how many were affected.t(4;14)
Pieces of chromosomes 4 and 14 have swapped places. It switches on genes that drive growth. Some newer medicines work well against it, which has softened its impact.
t(14;16) and t(14;20)
Less common swaps involving chromosome 14. They are often grouped as high risk, though the evidence is thinner because fewer people have them.
Gain or amplification of 1q
Extra copies of the long arm of chromosome 1. More copies usually carry more risk. Newer staging systems now count it.
Often reported with
- del(1p), a loss on chromosome 1
- Other high-risk changes
Two or more together
When two high-risk changes appear together, reports may say "double hit". This group usually needs the closest attention and is often offered a clinical trial.
Not sure whether this applies to you?
Ask an oncologistBehind the report
How is the chromosome test done?
The marrow sample
Taken during the bone marrow test from the back of the hip bone. No separate procedure is needed if it is planned in advance, so ask before the marrow test.
Picking out plasma cells
Plasma cells are often a small share of the sample. Good labs enrich or sort them first, sometimes printed as CD138-selected, so changes are not missed.
FISH testing
Fluorescent probes stick to specific chromosome regions. Under a microscope, missing, extra or swapped pieces show up as a changed pattern of coloured dots.
The report
Each probe is listed as detected or not detected, often with the share of cells affected. Results can take longer than routine blood tests.
What it means for the plan
If the result is high risk, what changes?
High-risk results usually lead to a plan that uses more medicines together, keeps treatment going longer and watches more closely. The aim is a deeper response, because depth of response matters more when the disease is likely to return.
What your team may discuss
A combination that includes an antibody medicine alongside the usual tablets and injections. An assessment for stem cell transplant if you are fit enough, sometimes with more than one transplant. Maintenance with more than one medicine. Sensitive tests for leftover cells. CION's haematology team evaluates the case, presents it to a tumour board, and coordinates transplant and specialist testing with qualified centres.
Who a stronger plan does not suit
A more intensive plan can be too much for someone who is frail, very elderly, or has serious heart, lung or kidney problems. In that case a high-risk result is balanced against side effects and quality of life, and a gentler plan may be the wiser choice.
What this page cannot tell you
It cannot tell you how your myeloma will behave. High risk describes a tendency in large groups, not a fixed course for you. Your haematologist reads the result together with stage, fitness and response.
What to ask at the next visit
Ask which changes were found, in what share of cells, and whether the plasma cells were sorted before testing. Ask how the result changed the plan, and what would happen if you chose a gentler path. Write the answers down so the whole family hears the same thing.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Did you know
Myeloma cells can gain new chromosome changes over time. If myeloma returns after treatment, your haematologist may repeat the FISH test, because a change that was absent at diagnosis can appear later and alter the next plan.
Commonly believed
What do families often fear wrongly about a high-risk result?
"High risk means treatment will not help."
Many people with high-risk changes respond well to treatment. The result tells your team to plan more carefully, not to give up. Newer medicines have narrowed the gap for some changes.
"Our children will get it because it is genetic."
These changes are in the myeloma cells only. They were not inherited and cannot be passed on. Your children do not need a test because of this result.
"Standard risk means we can relax about treatment."
Standard-risk myeloma still needs full treatment and regular follow-up. It is still myeloma, and it can still return.
"If FISH was not done, it is too late now."
It can often be done on a stored sample, or on the next marrow test. Ask your haematologist whether it is worth arranging.
On your report
How do you read the shorthand on a FISH report?
- del
- Deletion. A piece of a chromosome is missing.
- t( ; )
- Translocation. Pieces of the two chromosomes named inside the brackets have swapped places.
- p and q
- The short arm and the long arm of a chromosome.
- Gain or amp
- Extra copies of a region. Amplification means more copies than a simple gain.
- Hyperdiploid
- Extra copies of several odd-numbered chromosomes. Usually counted as standard risk.
- Not detected
- The probe did not find that change in the cells tested.
Questions we are asked
Common questions about high-risk myeloma
Is high-risk myeloma a different disease?
No. It is the same disease with features that suggest it may grow faster or return sooner. It is diagnosed and treated in the same way at first, but the plan is usually built with more medicines, closer monitoring and a longer maintenance phase.
Why was a chromosome test not done at our first hospital?
FISH needs a specialist laboratory and a sample taken with it in mind, so it is not always available. Ask whether the stored marrow sample can be sent now. If not, it can be planned for the next marrow test. CION's team can tell you what to ask for.
Can the risk result change over time?
The result at diagnosis stays on record, but myeloma can pick up new changes, especially when it returns. A repeat test at relapse can show a change that was not there before. That can shape which treatment comes next.
Does high risk mean a transplant is essential?
Not always. A transplant is often discussed for fit people with high-risk disease, but it depends on age, fitness, other illnesses and your own wishes. Some people are better served by a non-transplant plan. Talk through both paths with your haematologist.
What is the difference between FISH and karyotype?
A karyotype looks at all chromosomes in dividing cells, but myeloma cells divide slowly and often show nothing. FISH looks for specific known changes and works on non-dividing cells, so it is the preferred test for myeloma risk. Some reports include both.
Should we get a second opinion on a high-risk result?
It is reasonable, especially before choosing between very different plans. Bring the FISH report, marrow report, staging results and treatment so far. A second look can confirm the reading and check that the plan matches the risk.
Are clinical trials an option?
Often, yes. High-risk myeloma is an active area of research, and trials may offer newer combinations. Ask your haematologist whether any trial fits your situation. Taking part is always your choice, and you can still receive standard treatment if you decide against it.
Can diet or lifestyle change a high-risk result?
No. Chromosome changes in myeloma cells are not caused or reversed by diet. Good nutrition, staying active within your limits and avoiding infections help you get through treatment. Do not start supplements or stop any medicine without asking your team.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ) - Health Professional Version
- American Cancer Society — Multiple Myeloma Stages
- Cancer.Net — Multiple Myeloma
- Leukemia & Lymphoma Society — Myeloma
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Myeloma Staging: ISS and R-ISSHow chromosome results feed into the stageInduction Therapy: VRd, DRd and What They InvolveThe first treatment combinations explainedAm I Eligible for a Stem Cell Transplant?Often discussed after a high-risk resultMaintenance Therapy After Myeloma TreatmentWhy maintenance may be longer in high-risk disease
Talk to us
Have a FISH report you want explained?
Tell us what has been found so far. CION's haematology team will read the chromosome results with you and help you plan the next step. One helpline serves every CION centre.